3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
28
Phase 1
4
Phase 2
3
Phase 4
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Multiple Myeloma
2
Uterine Cervical Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Obesity
1
Nutrition Disorders
1
Neoplasms
1
Motor Activity
1
Hypertension
1
Diabetes Mellitus
1
Depression
1
Cardiovascular Diseases
1
Anus Neoplasms
1
Interventions
pembrolizumab
44
Nivolumab
29
Gemcitabine
28
Paclitaxel
19
Cisplatin
18
Ipilimumab
15
Carboplatin
14
Cyclophosphamide
13
Capecitabine
12
Dexamethasone
10
Bevacizumab
10
cemiplimab
9
Irinotecan
9
Docetaxel
9
Albumin-Bound Paclitaxel
9
130-nm albumin-bound paclitaxel
9
spartalizumab
8
Pemetrexed
8
Sorafenib
7
Rituximab
7
Cetuximab
7
fludarabine
6
Temozolomide
6
Taxes
6
Radiotherapy
6
Leucovorin
6
Fluorouracil
6
Azacitidine
6
Ascorbic Acid
6
lenvatinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Neoplasms
×
Therapeutics
×
Clear all
NCT03443635
2022-04-29
CHOP
Tulane University
Phase 1/2
Completed
7,192 enrolled
7 charts